These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25583363)

  • 21. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds.
    Rangel-Barajas C; Malik M; Mach RH; Luedtke RR
    Neuropharmacology; 2015 Jun; 93():179-90. PubMed ID: 25698528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The action of a negative allosteric modulator at the dopamine D
    Draper-Joyce CJ; Verma RK; Michino M; Shonberg J; Kopinathan A; Klein Herenbrink C; Scammells PJ; Capuano B; Abramyan AM; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Sci Rep; 2018 Jan; 8(1):1208. PubMed ID: 29352161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, in silico, and in vitro studies of novel dopamine D
    Elek M; Djokovic N; Frank A; Oljacic S; Zivkovic A; Nikolic K; Stark H
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000486. PubMed ID: 33615541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
    Carli M; Kolachalam S; Aringhieri S; Rossi M; Giovannini L; Maggio R; Scarselli M
    Curr Neuropharmacol; 2018 Jan; 16(2):222-230. PubMed ID: 28521704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways.
    Taylor M; Grundt P; Griffin SA; Newman AH; Luedtke RR
    Synapse; 2010 Mar; 64(3):251-66. PubMed ID: 19924694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
    Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
    J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
    Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.
    Newman AH; Grundt P; Cyriac G; Deschamps JR; Taylor M; Kumar R; Ho D; Luedtke RR
    J Med Chem; 2009 Apr; 52(8):2559-70. PubMed ID: 19331412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands.
    Huang Y; Luedtke RR; Freeman RA; Wu L; Mach RH
    J Med Chem; 2001 May; 44(11):1815-26. PubMed ID: 11356115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice.
    Boateng CA; Bakare OM; Zhan J; Banala AK; Burzynski C; Pommier E; Keck TM; Donthamsetti P; Javitch JA; Rais R; Slusher BS; Xi ZX; Newman AH
    J Med Chem; 2015 Aug; 58(15):6195-213. PubMed ID: 26203768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D
    Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR
    Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and Synthesis of Conformationally Flexible Scaffold as Bitopic Ligands for Potent D
    Kim HY; Lee JY; Hsieh CJ; Taylor M; Luedtke RR; Mach RH
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly Selective Dopamine D
    Reilly SW; Griffin S; Taylor M; Sahlholm K; Weng CC; Xu K; Jacome DA; Luedtke RR; Mach RH
    J Med Chem; 2017 Dec; 60(23):9905-9910. PubMed ID: 29125762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
    Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L
    J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functionally selective dopamine D₂, D₃ receptor partial agonists.
    Möller D; Kling RC; Skultety M; Leuner K; Hübner H; Gmeiner P
    J Med Chem; 2014 Jun; 57(11):4861-75. PubMed ID: 24831693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.
    Wood M; Ates A; Andre VM; Michel A; Barnaby R; Gillard M
    Mol Pharmacol; 2016 Feb; 89(2):303-12. PubMed ID: 26655303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.
    Luedtke RR; Mishra Y; Wang Q; Griffin SA; Bell-Horner C; Taylor M; Vangveravong S; Dillon GH; Huang RQ; Reichert DE; Mach RH
    ACS Chem Neurosci; 2012 Dec; 3(12):1050-62. PubMed ID: 23259040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine receptor ligands. Part 18: (1) modification of the structural skeleton of indolobenzazecine-type dopamine receptor antagonists.
    Robaa D; Enzensperger C; Abul Azm Sel D; El Khawass el S; El Sayed O; Lehmann J
    J Med Chem; 2010 Mar; 53(6):2646-50. PubMed ID: 20180564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel, Selective, and Developable Dopamine D
    Micheli F
    ChemMedChem; 2017 Aug; 12(16):1254-1260. PubMed ID: 28426179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
    MacKenzie RG; VanLeeuwen D; Pugsley TA; Shih YH; Demattos S; Tang L; Todd RD; O'Malley KL
    Eur J Pharmacol; 1994 Jan; 266(1):79-85. PubMed ID: 7907989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.